AstraZeneca & Novartis
7 shared events · Importance 3 · Last updated Sep 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
AstraZeneca: One of the nine signatories of the open letter urging the European Union to boost pharmaceutical investment and speed up trials. The appeal signals concern over European competitiveness but does not change its near-term financial outlook.
Novartis: A signatory of the open letter urging the European Union and member states to strengthen the region's pharmaceutical industry. The appeal is aimed at improving the investment and regulatory climate it operates in.
Sep 22, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca participated in the symposium, contributing to discussions on decarbonization and green chemistry.
Novartis: Novartis participated in the symposium, demonstrating its commitment to green chemistry and sustainable manufacturing.
Jul 20, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca is cited as a peer whose total shareholder returns have outpaced Novartis since Narasimhan became CEO, highlighting relative underperformance concerns.
Novartis: Novartis is the central entity of the event; the del-desiran Phase III failure and prior pelacarsen setback erased roughly $30 billion in market value and intensified investor scrutiny of its M&A strategy and pipeline.
Sep 08, 2026 · 21 articles
Business
AstraZeneca: Listed among recent acquirers of radiopharmaceutical companies or assets, part of the consolidation wave that frames the Telix-ITM transaction.
Novartis: Dominant radiopharmaceutical player with Pluvicto and Lutathera faces a more vertically integrated competitor as Telix absorbs ITM's isotope supply and neuroendocrine tumor pipeline.
Sep 21, 2026 · 6 articles
Business
AstraZeneca: AstraZeneca is mentioned as a prior acquirer of KC Pharmaceuticals, illustrating sector M&A activity.
Novartis: Novartis is mentioned as the maker of Pluvicto, a competitor to a Lantheus-Eli Lilly therapeutic that was abandoned.
Aug 03, 2026 · 7 articles
Business
AstraZeneca: AstraZeneca is listed as a previous employer of Jenkins; no direct impact from this event.
Novartis: Novartis is listed as a previous employer of Jenkins; no direct impact from this event.
Jul 15, 2026 · 6 articles
Regulatory
Novartis: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how AstraZeneca and Novartis interact across events, view sentiment trends, and discover connected entities.
Open Dashboard